Page 2


  • FTC
    Image attribution tooltip
    Carol Highsmith. (2005). "Apex Bldg." [Photo]. Retrieved from Wikimedia Commons.
    Image attribution tooltip

    AbbVie’s Cerevel deal hits an uncommon roadblock

    A “second request” from the Federal Trade Commission could protract the timing of AbbVie’s proposed acquisition, which is slated to close around the middle of the year.

  • Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    Rick Gonzalez, longtime AbbVie CEO, to step down in July

    The veteran executive, who guided AbbVie through its separation from Abbott Laboratories, will be succeeded by Chief Operating Officer Robert Michael. 

  • Packaging for Iovance Biotherapeutics' cellular medicine Amtagvi is held by a technician wearing gloves.
    Image attribution tooltip
    Courtesy of Iovance Biotherapeutics
    Image attribution tooltip

    Iovance, with approval of ‘TIL’ cell therapy, readies for complex launch

    The biotech set a price of roughly $515,000 per patient for its therapy Amtagvi, the first to be approved based on a decades-old technique of using tumor-infiltrating lymphocytes. 

    FDA
  • Recession arrow, Graph showing business decline on led screen
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    FDA puts hold on Rapt trials of drug for eczema, asthma

    Rapt reported one case of liver failure in a study participant who received the biotech’s drug, which is seen by analysts as a possible competitor to Dupixent.

  • A general view of AstraZeneca is seen during Prime Minister Scott Morrison's visit on August 19, 2020 in Sydney, Australia.
    Image attribution tooltip
    Lisa Maree Williams via Getty Images
    Image attribution tooltip

    AstraZeneca gets new Tagrisso OK as drug succeeds in another trial

    The FDA approved the targeted therapy together with chemo for first-line metastatic lung cancer, while fresh trial results supported earlier use.

  • A 3D visualization of neurons and neural network with signals.
    Image attribution tooltip
    Evgenii Kovalev via Getty Images
    Image attribution tooltip
    ALS drug development

    ALS drug from Denali, Sanofi falls short in mid-stage study

    The disclosure the experimental therapy missed its trial goal comes after Sanofi had earmarked the drug for advancement into Phase 3.

  • A sign showing Gilead's logo
    Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    Gilead reviewing drug acquired in $5B buyout after latest setback

    The FDA paused enrollment in the only remaining tests of the drug, as Gilead reviews the program it acquired through a buyout of biotech Forty Seven.

  • A photo of a building with the Astellas Pharma logo.
    Image attribution tooltip
    Courtesy of Astellas Pharma
    Image attribution tooltip

    Astellas teams up with startup Kelonia to make ‘in vivo’ cell therapies

    Kelonia will receive $40 million upfront through the partnership, and could receive $35 million more if Astellas opts into another program.

  • A photograph of a Sarepta building in Boston, MA
    Image attribution tooltip
    Courtesy of Sarepta
    Image attribution tooltip

    FDA to review expanded use of Sarepta Duchenne gene therapy

    The agency will decide by June 21 whether to broaden eligibility for Elevidys, and won’t convene a group of outside experts beforehand.

  • Red human heart drawing on blue background
    Image attribution tooltip
    Jolygon via Getty Images
    Image attribution tooltip

    Alnylam changes to heart drug trial spark doubts, sinking shares

    Analysts pressed Alnylam executives on the reasons for changes to HELIOS-B, a Phase 3 study in ATTR amyloidosis with cardiomyopathy that is important to the company’s future. 

  • Image of business people walking past building with Wall Street sign.
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip

    Aurinia to cut research after sale process fails to find a buyer

    The lupus drug developer said it engaged more than 60 parties during its eight-month business review, but only one expressed interest before walking away.

  • An illustration of two lungs on a scientific background colored orange.
    Image attribution tooltip
    Mohammed Haneefa Nizamudeen via Getty Images
    Image attribution tooltip

    Intellia, ReCode partner on genetic medicines for cystic fibrosis

    The partnership will use Intellia's "DNA writing” technology, and focus on people with the lung disease who have limited or no available treatments

  • A firefly alights on a single plant stalk at dust.
    Image attribution tooltip
    Jeremy Hogan via Getty Images
    Image attribution tooltip
    Emerging biotech

    Versant-backed Firefly Bio wants to make the next generation of ADCs

    Armed with $94 million in funding, the biotech is marrying antibody-drug conjugates with protein degraders to create a new kind of cancer medicine.

  • A 3D illustration of a nerve cell on a black background
    Image attribution tooltip
    koto_feja via Getty Images
    Image attribution tooltip
    Emerging biotech

    Hunting a non-opioid painkiller, a biotech reveals plans to chase Vertex

    Latigo Biotherapeutics has raised $135 million to develop drugs that block NaV1.8, the target of a Vertex therapy that just succeeded in Phase 3 trials.

  • A hospital bracelet is attached to a newborn infant's wrist.
    Image attribution tooltip
    Nenov via Getty Images
    Image attribution tooltip

    Sage offers details on launch of new postpartum depression pill

    The company and partner Biogen say signs from payers and doctors suggest the launch of Zurzuvae, the first oral therapy for PPD, is off to a good start.

  • The sign identifying the FDA headquarters in front of its building in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Ipsen drug approved by FDA for early pancreatic cancer

    The clearance of Onivyde for first-line pancreatic adenocarcinoma triggers a $225 million payment to Merrimack, from whom Ipsen bought the drug.

  • A financial graph on an abstract background
    Image attribution tooltip
    monsitj via Getty Images
    Image attribution tooltip

    LianBio to shut down, return cash to investors

    The biotech is planning to dissolve less than four years after launching with plans to license drugs and market them in China and other Asian countries.

  • A photo of a Biogen sign
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip
    New Alzheimer's drugs

    Biogen has a fuzzy line of sight on prized Alzheimer’s drug

    CEO Chris Viehbacher said there are about 3,800 U.S. patients on a registry for Leqembi. But Biogen doesn’t have all the details, as development partner Eisai is leading commercial efforts.

  • Left: Anthony Philippakis, right: Krishna Yeshwant
    Image attribution tooltip
    Permission granted by GV
    Image attribution tooltip
    Q&A

    Two GV investors on biotech’s reset and building their next drug startups

    Newly named general partner Anthony Philippakis and managing partner Krishna Yeshwant discussed biotech’s newfound optimism and their investing “North Star.”

  • Image attribution tooltip
    Elizabeth Regan / Industry Dive
    Image attribution tooltip

    Kalvista pill succeeds in late-stage study for rare swelling disorder

    The biotech's drug quickly alleviated symptoms of the swelling attacks associated with hereditary angioedema, supporting the idea it could be an oral alternative to existing medicines.

    Updated Feb. 13, 2024
  • Blue double exposure of money coins stacking with bar graph for financial and investment business concept.
    Image attribution tooltip
    Dilok Klaisataporn
    Image attribution tooltip

    BioAge raises $170M to back Phase 2-ready obesity drug

    BioAge’s Series D will fund a study combining its medicine with Eli Lilly’s Zepbound, a strategy the company hopes could help people lose weight while maintaining muscle mass.

  • A 3D visualization of antibody drug conjugates.
    Image attribution tooltip
    Love Employee via Getty Images
    Image attribution tooltip

    ADC startup ProfoundBio, led by Seagen veterans, raises $112M

    The Series B round will fund development of antibody-drug conjugates now in clinical testing, among them a rival to AbbVie’s ovarian cancer drug Elahere.

  • Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    Gilead to buy CymaBay in $4.3B deal for liver disease drug

    The proposed acquisition is a bet on CymaBay’s drug seladelpar, which is now under FDA review in a chronic liver disease called primary biliary cholangitis.

  • An anatomical model of the heart sits on a desk in a doctor's office
    Image attribution tooltip
    Ivan-Balvan via Getty Images
    Image attribution tooltip

    CSL heart drug misses goal in large study

    The failure of CSL’s plasma-derived infusion, which contains a protein in “good” cholesterol, follows a similar path as pills from Lilly, Merck, Pfizer and Roche.

  • A stock illustration of skin and fat tissue cells, viewed at cross section and colored pale pink.
    Image attribution tooltip
    Benjamin Toth via Getty Images
    Image attribution tooltip

    Alys launches with $100M and a pipeline of skin disease drugs

    European venture firm Medicxi built the startup by combining six of its portfolio companies, similar to when it merged 10 startups to form Centessa Pharmaceuticals in 2021.